References
- Ciardiello F, Tortora G. Epidermal growth factor recep-tor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003; 39: 1348–1354.
- Giaccone G, Johnson DH, Manegold C, et al. Gefitinib in combination with gemcitabine and cispatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22: 777–784.
- Dancey JE, Freidin B. Targeting epidermal growth fac-tor receptor - are we missing the mark? Lancet 2003; 362: 62–64.
- Cunningham D, Humblet Y, Siena S, et al. A random-ized comparison of cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–345.
- Hurwitz H, Fehrenbacher L, Novotny W et a al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342.
- Arteaga CL, Baselga J. Clinical trial design and end-points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Clin Cancer Res 2003; 9: 1579–89.
- Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Nati Cancer Inst 2001; 93: 1852–1857.
- Bianco R, Shin I, Ritter C, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003; 22: 2812-2822.
- Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor activity of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61: 5090–5101.
- Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a small molecule VEGF receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to EGF receptor-targeted drugs. Clin Cancer Res 2004; 10: 784–793.